Breast Cancer

Surgical Therapy

Adjuvant Therapy

1st Line MBC Therapy

2nd or 3rd Line MBC Therapy

Pre-Op Therapy

No Trial Currently Available

IRB# 6256
I-SPY 2: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

No Trial Currently Available

IRB# 17887
DS-8201a Compared to Treatment of Physician’s Choice for HER2-low Unresectable/Metastatic Breast Cancer

IRB# 19200
A Dose Escalation/Expansion Study of OP-1250 in Subjects with Advanced Breast Cancer

IRB# 21522
A Study of ZN-c5 in Subjects with Advanced Breast Cancer

IRB# 20440
CT7001 Alone and In Combination With Anti-Cancer Treatments in Patients with Advanced Malignancies

IRB# 6256
I-SPY 2: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

No Trial Currently Available

IRB# 17887
DS-8201a Compared to Treatment of Physician’s Choice for HER2-low Unresectable/Metastatic Breast Cancer

IRB# 19200
A Dose Escalation/Expansion Study of OP-1250 in Subjects with Advanced Breast Cancer

IRB# 21522
A Study of ZN-c5 in Subjects with Advanced Breast Cancer

IRB# 20440
CT7001 Alone and In Combination With Anti-Cancer Treatments in Patients with Advanced Malignancies

TRIPLE NEGATIVE (ER/PR NEGATIVE HER2 NEGATIVE) Studies

“Heavily Pretreated” Therapy

“Heavily Pretreated” Therapy

No Trial Currently Available

IRB# 19489
Targeting Metastatic Breast Cancer and Breast Cancer Stem Cells with Lutathera

IRB# 22191
Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in Early-Stage Breast Cancer

IRB# 20679
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment

CROSS-DISEASE TRIALS:

IRB 19992
EAY131 (MATCH)

IRB 18084
S1609 DART

http://www.ohsu.edu/research/rda/so/knight.php
Breast Cancer

Surgical Therapy

Pre-Op Therapy

Adjuvant Therapy

1st Line MBC Therapy

2nd or 3rd Line MBC Therapy

Heavily Pre-Treated Therapy

HER2 POSITIVE

IRB# 6256
I-SPY 2: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

No Trial Currently Available

No Trial Currently Available

IRB # 19078
S1501: Prospective Evaluation of carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER2+ BC, Phase III

IRB #19830
T-DM1 and Palbociclib in Metastatic HER2+ BC

IRB #20112
T-DM1 and Tucatinib or Placebo in Metastatic HER2+ BC

IRB#20679
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment

CROSS-DISEASE TRIALS:

IRB 19992
EAV131 (MATCH)

IRB 18084
S1609 DART

IRB 19489
Targeting Metastatic Breast Cancer and Breast Cancer Stem Cells with Lutathera

Key

- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php

03 Dec 2020